6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington. D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR I5d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2004
Novogen Limited
(Translation of registrant's name into English)
140 Wicks Road, North Ryde, NSW, 2113, Australia
(Address of principal executive office)
[Indicate by check mark whether the registrant files or will file
annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F v Form 40-F
[Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934. Yes No
[If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2 (b):
82- ________________ .1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Novogen Limited
(Registrant)
Date 26 March, 2004 By Ronald Lea Erratt Company Secretary

ASX & MEDIA RELEASE
26 MARCH 2004

Late breaking clinical trial results of investigational
anti-cancer drug phenoxodiol among four abstracts to be
presented at the American Association for Cancer
Research Annual Meeting

Novogen Limiteds subsidiary, Marshall Edwards, Inc.
(LSE AIM: MSH and Nasdaq: MSHL) has just made the
following announcement to the London Stock
Exchanges Alternative Investment Market.

WASHINGTON, D.C. March 26, 2004 Marshall Edwards, Inc.
(Nasdaq: MSHL), confirmed today that four abstracts,
including two from clinical trials on its
investigational anti-cancer drug phenoxodiol,
are to be presented at the 95th Annual Meeting
of the American Association for Cancer Research (
AACR) in Orlando, Florida, March 27-31, 2004,
Orange County Convention Center. The abstracts
for these presentations are available from AACR,
which can be obtained using the information below.

*Late-breaking entry: Interim results of a Phase
Ib/IIa study of oral phenoxodiol in patients with
late-stage, hormone-refractory prostate cancer
Abstract No. LB-214
Late-Breaking Abstracts: Poster Session 2
Tuesday 3/30/04 1:00 PM-5:00 PM
Hall B4-D

Phenoxodiol phase Ib/II study in patients
with recurrent ovarian cancer that are resistant
to second line chemotherapy
Abstract No. 4457: http://aacr04.agora.com/planner/
displayabstract.asp?presentationid=5467
Poster Session
Tuesday 3/30/2004
1:00 PM-5:00 PM
Hall B4-D

Phenoxodiol a chemosensitizer in taxotere-resistant
ovarian cancer cells
Abstract No. 4885: http://aacr04.agora.com/planner/
displayabstract.asp?presentationid=6039
Poster Session
Wednesday 3/31/2004
8:00 AM-12:00 PM
Hall B4-D

Phenoxodiol, a novel isoflavone, promotes
g1/s arrest by upregulation of p21 in head
and neck squamous and salivary gland carcinoma
cell lines
Abstract No. 1515: http://aacr04.agora.com/planner/
displayabstract.asp?presentationid=4950
Minisymposium
Sunday 3/28/2004
2:00 PM-5:30 PM
Hall F1-2

Phenoxodiol works by removing the proteins
(XIAP, c-FLIP) within the cancer cell that are
responsible in large part for preventing the
ability of the cancer cell to be killed by the
body and by chemotoxic drugs. When these proteins
are removed, the cancer cell is sensitive to the
body's normal defense mechanisms that are designed
to eliminate cancerous cells. This synergistic
mechanism also leads to phenoxodiol enhancing in a
very potent way the sensitivity of cancer cells to
the killing ability of standard anti-cancer drugs,
as well as reversing chemo-resistance in cancer
cells and restoring their sensitivity to those
standard drugs. Phenoxodiol is an investigational
drug and has not yet been approved for marketing
in the U.S.
Marshall Edwards, Inc., manages its international
research and development programs using the expertise
and clinical research capabilities of universities
and hospitals in the U.S., Australia and Europe.
Marshall Edwards, Inc., has licensed rights to
bring phenoxodiol to market globally from
its parent company, Novogen Limited (Nasdaq: NVGN).
Novogen is developing a range of therapeutics
across the fields of oncology, cardiovascular
disease and inflammatory diseases based on its
phenolic drug technology platform.
More information on phenoxodiol and on the
Novogen group of companies can be found at
www.marshalledwardsinc.com and www.novogen.com.

Statements included in this press release that are
not historical in nature are forward-looking
statements within the meaning of the safe harbor
provisions of the Private Securities Litigation
Reform Act of 1995. You should be aware that
our actual results could differ materially
from those contained in the forward-looking
statements, which are based on managements current
expectations and are subject to a number of risks
and uncertainties, including, but not limited to,
our failure to successfully commercialize our
product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such
approval, of our product candidates; uncertainties
in clinical trial results; our inability to maintain
or enter into, and the risks resulting from our
dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization,
marketing, sales and distribution of any products;
competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary
rights to third party patents and intellectual property
to operate our business; our inability to operate our
business without infringing the patents and proprietary
rights of others; general economic conditions; the
failure of any products to gain market acceptance;
our inability to obtain any additional required
financing; technological changes; government
regulation; changes in industry practice; and
one-time events. We do not intend to update
any of these factors or to publicly announce
the results of any revisions to these
forward-looking statements.

CONTACT: US-Australia: Mr Christopher Naughton,
CEO, Marshall Edwards, Inc., + 61.2.9878 0088